tirzepatide cardiovascular outcomes trial Matches Dulaglutide in Large CV Trial: SURPASS-CVOT Tirzepatide cardiovascular event risk assessment:

Current evidence suggests that GLP-1 receptor agonists can be safely used in patients with well-controlled hypothyroidism, though several important considerations warrant attention

If you develop a widespread rash, mouth ulcers, or other systemic symptoms alongside joint pain, contact your healthcare provider promptly

Lancet Diabetes Endocrinol 2(6):474480 Gong Q, Gregg EW, Wang J, An Y, Zhang P, Yang W, Li H, Li H, Jiang Y, Shuai Y, Zhang B, Zhang J, Gerzoff RB, Roglic G, Hu Y, Li G, Bennett PH (2011) Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study

The documented route is subcutaneous a shallow injection into the fat layer just under the skin (abdomen, flank or thigh), using a fine insulin needle

As a result many clinicians who prescribe them question their sustainability